Paper28296257
Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome.
Bowman SJ and 22 others. Arthritis Rheumatol, 2017. Cited by 217 papers, by iCite.
Cite this record
ConductScience Library. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome. Papers, record 28296257. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28296257
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antirheumatic Agents | Major topic |
| Fatigue | Major topic |
| Rituximab | Major topic |
| Sjogren's Syndrome | Major topic |
| Xerostomia | Major topic |
| Adult | |
| Aged | |
| Cost-Benefit Analysis | |
| Double-Blind Method | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Odds Ratio | |
| Patient Reported Outcome Measures | |
| Quality of Life | |
| Quality-Adjusted Life Years | |
| Treatment Outcome | |
| United Kingdom | |
| Visual Analog Scale |
Source PubMed
Grants7
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| MR/N003063/1 | Medical Research Council | United Kingdom | PubMed | |
| 21268 | Versus Arthritis | United Kingdom | PubMed | |
| G0800629 | Medical Research Council | United Kingdom | PubMed | |
| 18810 | Versus Arthritis | United Kingdom | PubMed | |
| RC-PG-0407-10054 | Department of Health | United Kingdom | PubMed | |
| 18475 | Arthritis Research UK | United Kingdom | PubMed | |
| 20639 | Versus Arthritis | United Kingdom | PubMed |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT07145060 | A Study of Yiqi Yangyin Formula in the Treatment of Primary Sjogren's Syndrome | Results |
Source ClinicalTrials.gov
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Erratum in | 33460295 | Incorrect Data in Tables and Omission of Author Name in the Article by Bowman et al (Arthritis Rheumatol, July 2017). | https://conductscience.org/library/papers/33460295 | PubMed |
| Comment in | 28296253 | Editorial: Rituximab in the Treatment of Sjögren's Syndrome: Is It the Right or Wrong Drug? | https://conductscience.org/library/papers/28296253 | PubMed |
Cited by137
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 217 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42970028 | A Systematic Literature Review on the Economic Burden of Sjögren's Disease. | Pharmacoeconomics | 2026 | https://conductscience.org/library/papers/42970028 | PubMed |
| 42941814 | Host-Microbe Crosstalk in Sjögren's Disease: Epithelial Type I Interferon Amplification, Loss of Short-Chain Fatty Acid Restraint, and the Effector-Phase Focus of Validated Therapy. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42941814 | PubMed |
| 42857216 | Tregs transduced with a Ro60-reactive TCR have increased immunosuppressive functions in Sjögren's disease. | iScience | 2026 | https://conductscience.org/library/papers/42857216 | PubMed |
| 42840875 | Histone lactylation: a metabolic-epigenetic bridge linking glycolysis to salivary gland fibrosis in Sjögren's disease. | Front Immunol | 2026 | https://conductscience.org/library/papers/42840875 | PubMed |
| 42787283 | B-cell centrality dictates therapeutic efficacy across autoimmune diseases: a systematic review. | Front Immunol | 2026 | https://conductscience.org/library/papers/42787283 | PubMed |
| 42780594 | From immune activation to symptom burden: mechanisms and translational implications of immune-symptom uncoupling in Sjögren's disease. | Front Immunol | 2026 | https://conductscience.org/library/papers/42780594 | PubMed |
| 42528857 | Spatiotemporal orchestration of the salivary gland immune microenvironment in Sjögren's disease: a multidimensional framework of epithelial licensing, lymphoid neogenesis, and stromal remodeling. | Front Immunol | 2026 | https://conductscience.org/library/papers/42528857 | PubMed |
| 42488665 | Janus kinase inhibitor use and incident dry eye disease in rheumatoid arthritis: a real-world cohort study. | Front Immunol | 2026 | https://conductscience.org/library/papers/42488665 | PubMed |
| 42449965 | From Molecular Pathophysiology to Clinical Trial Design in Sjögren's Disease: A Three-Axis Framework. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42449965 | PubMed |
| 42419786 | Integrating basal and reserve salivary function defines clinically anchored functional phenotypes and contextualises salivary end points in Sjögren's disease. | RMD Open | 2026 | https://conductscience.org/library/papers/42419786 | PubMed |
| 42414970 | Age-specific reference values for unstimulated whole saliva flow rate in primary Sjögren's syndrome: a cross-sectional study. | BMC Oral Health | 2026 | https://conductscience.org/library/papers/42414970 | PubMed |
| 42342283 | Emerging treatments for Sjögren's disease: promising drugs on the horizon. | RMD Open | 2026 | https://conductscience.org/library/papers/42342283 | PubMed |
| 42260594 | Molecular classification of primary Sjögren's syndrome based on salivary gland omics. | Arthritis Res Ther | 2026 | https://conductscience.org/library/papers/42260594 | PubMed |
| 42251196 | Fatigue in Sjögren's Disease - Integrating Biomedical and Psychosocial Aspects: A Narrative Review. | Rheumatol Ther | 2026 | https://conductscience.org/library/papers/42251196 | PubMed |
| 42194915 | When Dryness Extends to the Brain: Brain-Related Non-Sicca Manifestations of Sjögren's Disease. | J Clin Med | 2026 | https://conductscience.org/library/papers/42194915 | PubMed |
| 42123721 | Molecular Insights into Oral Manifestations in Sjögren's Disease. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42123721 | PubMed |
| 42043506 | [Current treatment, foreseeable newcomer and new treatment approaches for Sjögren's disease]. | Z Rheumatol | 2026 | https://conductscience.org/library/papers/42043506 | PubMed |
| 42008018 | The Evolving Landscape of CAR T-Cell Therapy in Autoimmune Diseases: A State-of-the-Art Review (2025). | Clin Rev Allergy Immunol | 2026 | https://conductscience.org/library/papers/42008018 | PubMed |
| 41922188 | [Research progress on the application of telitacicept in rheumatism and autoimmune diseases]. | Zhejiang Da Xue Xue Bao Yi Xue Ban | 2026 | https://conductscience.org/library/papers/41922188 | PubMed |
| 41912841 | Evaluation of Effectiveness of Long-Term Therapy with Russian Rituximab Biosimilar (Acellbia) in Sjogren's Disease in Real Clinical Practice. | Dokl Biochem Biophys | 2026 | https://conductscience.org/library/papers/41912841 | PubMed |
Data2
The data bank entries PubMed's record names. Trial numbers are under Trials.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- References
- Genes
- Drugs
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28296257
GET https://conductscience.org/api/papers/v1/28296257/authors?page=2